ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Cognitive Dysfunction
Dementia
Mental Disorders
Psychotic Disorders
Brain Diseases
Neurodegenerative Diseases

Alzheimer's Disease trials near San Francisco, CA, USA:

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

Palo Alto, California, United States and 45 other locations

The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly...

Enrolling
Alzheimer Disease
Aging
Diagnostic Test: California Cognitive Assessment Battery
Neurobehavioral Systems

Berkeley, California, United States

on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: E2814
Drug: Lecanemab

Phase 2

Eisai
Eisai

San Francisco, California, United States and 34 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Active, not recruiting
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

San Francisco, California, United States and 109 other locations

-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.Part A consists of a Screening Period (up t...

Enrolling
Alzheimer's Disease
Healthy Elderly
Drug: Placebo
Drug: NMRA-323511

Phase 1

Neumora Therapeutics

Walnut Creek, California, United States and 24 other locations

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease...

Begins enrollment in 1 month
Alzheimer's Disease
Other: Placebo
Drug: KarXT

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Palo Alto, California, United States and 114 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Palo Alto, California, United States and 102 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

San Francisco, California, United States of America and 246 other locations

capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 o...

Begins enrollment in 5 months
Alzheimer Disease
Agitation
Drug: KarX-EC
Drug: KarXT

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Walnut Creek, California, United States and 142 other locations

study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

San Francisco, California, United States and 205 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems